Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study.

Fiche publication

Date publication

mai 2025

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Dr VERNEREY Dewi , Mme HENRIQUES Julie , Mme MEURISSE Aurélia

Tous les auteurs :
Depotte L, Nay P, Borg C, Meurisse A, Henriques J, Bennouna J, De La Fouchardière C, Tougeron D, Mazard T, Chibaudel B, Tournigand C, Vernerey D, Pigneur F, Andre T, Cohen R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40389373

Résumé

Sarcopenia and growth differentiation factor 15 (GDF-15) are linked to poor cancer survival. In this exploratory analysis, we evaluated their interaction with nivolumab-ipilimumab efficacy in chemoresistant metastatic colorectal cancer (mCRC) harboring microsatellite instability and/or mismatch-repair deficiency (MSI/dMMR), based on the final survival analysis of the NIPICOL phase II trial.